GAITHERSBURG, Md., Feb. 13 Lentigen Corporation todayannounced the company is moving its corporate headquarters and manufacturingfacilities from the University of Maryland Baltimore County TechCenter to anew 26,000 square-foot facility in Gaithersburg.
Located along Maryland's I-270 technology corridor, the expanded facilitywill accommodate Lentigen's future growth needs as a leading developer andmanufacturer of lentiviral vectors and proteins for a wide range oftherapeutic and research applications. Two self-contained suites will allowsimultaneous multi-product manufacture in compliance with FDA-regulatedcurrent good manufacturing practices and EMEA regulatory standards.
"We are very pleased to have found a facility that will meet our expansionrequirements for both research-grade and clinical-grade operations," said TimRavenscroft, Lentigen's chief executive officer. "Located in the heart ofMaryland's technology corridor, we will be well situated to attract talentedindividuals to our growing organization and to meet the increasing needs ofour partners and customers."
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused onthe development of lentiviral vector technology for a wide range oftherapeutic, vaccine and research applications in biotechnology and medicine.Lentiviral vectors are the most efficient vehicles for the delivery of genesor gene silencing sequences stably into cells. Lentigen is a highlycollaborative company, co-developing lentiviral vector-based products across abroad spectrum of bench to clinical applications. Partnerships include TheNational Institutes of Health, The University of Pennsylvania, ThermoFisherScientific and The U.S. Army. For further information, visithttp://www.lentigen.com/Contact: Gregory Tiberend [email protected]
Meghan Feeks [email protected]
Richard Lewis Communications, Inc. 212-827-0020
SOURCE Lentigen Corporation